RT Journal Article
SR Electronic
A1 Nichols, Emma Hitt
T1 Targeting Telomerase with GV1001 Vaccine Does Not Prolong OS in Advanced Pancreatic Cancer
JF MD Conference Express
YR 2013
FD SAGE Publications
VO 13
IS 6
SP 22
OP 22
DO 10.1177/155989771306017
UL http://mdc.sagepub.com/content/13/6/22.1.abstract
AB Sequential or concurrent treatment with the vaccine GV100 with chemotherapy does not result in a survival advantage in patients with advanced pancreatic cancer. This article discusses data from the fourth interim analysis of the Gemcitabine and Capecitabine With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer study [TeloVac; NCT00425360; Middleton GW et al. J Clin Oncol 2013 (suppl; abstr LBA4004)].